DREW SATTERFIELD: Open Payments
NPI 1316328735 · CAPE GIRARDEAU, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,980 in 110 payments from 23 companies in 2025. Trend: 2023 $1,598 · 2024 $1,615 · 2025 $1,980
Food & beverage: $1,980
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $642 |
| Lilly USA, LLC | 11 | $171 |
| AstraZeneca Pharmaceuticals LP | 4 | $161 |
| Eisai Inc. | 5 | $146 |
| Dexcom, Inc. | 13 | $139 |
| Sumitomo Pharma America, Inc. | 6 | $113 |
| Otsuka America Pharmaceutical, Inc. | 5 | $100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $81 |
| Novo Nordisk Inc | 4 | $63 |
| Radius Health, Inc. | 3 | $55 |
Products named: VRAYLAR, QULIPTA, MOUNJARO, Leqembi, Dexcom G6 Transmitter, FARXIGA, GEMTESA, REXULTI.
Industry payments across MO — which companies pay providers there.
